Search research articles
Contact Us
Filters
Showing results (181-190 of 229) with videos related to
Page
of 23
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R E Miller, A Leary, C L Scott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2014
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial
A Adenis, J-Y Blay, B Bui-Nguyen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 4, 2017
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
A Poveda, J M Del Campo, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2024
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
A Alvarez Secord, S N Lewin, C G Murphy, et al.
ESMO Open
|
September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort
R Varnier, D Pérol, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 30, 2025
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial
J-Y Blay, Q Devin, M Toulmonde, et al.
British Journal of Cancer
|
January 11, 2017
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group
P-E Heudel, M Fabbro, C Roemer-Becuwe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2013
Quality indicators in ovarian cancer surgery: report from the French Society of Gynecologic Oncology (Societe Francaise d'Oncologie Gynecologique, SFOG)
D Querleu, I Ray-Coquard, J M Classe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2014
Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group
M Toulmonde, S Bonvalot, I Ray-Coquard, et al.
Page
of 23
Search research articles
Search
Showing results (181-190 of 229) with videos related to
Sort By:
Page
of 23
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R E Miller, A Leary, C L Scott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 15, 2014
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial
A Adenis, J-Y Blay, B Bui-Nguyen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 4, 2017
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
A Poveda, J M Del Campo, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 1, 2024
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial
A Alvarez Secord, S N Lewin, C G Murphy, et al.
ESMO Open
|
September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort
R Varnier, D Pérol, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 30, 2025
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial
J-Y Blay, Q Devin, M Toulmonde, et al.
British Journal of Cancer
|
January 11, 2017
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group
P-E Heudel, M Fabbro, C Roemer-Becuwe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2013
Quality indicators in ovarian cancer surgery: report from the French Society of Gynecologic Oncology (Societe Francaise d'Oncologie Gynecologique, SFOG)
D Querleu, I Ray-Coquard, J M Classe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2014
Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group
M Toulmonde, S Bonvalot, I Ray-Coquard, et al.
Page
of 23